Vanda's Q2 Loss Deepens to $62.5M as HETLIOZ Erodes and Cash Burn Accelerates
VNDA sits 16% above its 52-week low of $4.14.
Summary
Vanda's Q2 loss widened to $62.5M as HETLIOZ sales cratered 66% and spending surged. Cash reserves dropped to $170M, and a new 100% tariff on drug imports looms.
Key Events · Earnings and Guidance · VNDA
-
Q2 Loss More Than Doubles
Net loss reached $62.5M ($1.04/share) compared with $27.2M ($0.46/share) in Q2 2025, driven by a 68% jump in R&D and an 11% rise in SG&A.
-
HETLIOZ Sales Collapse
HETLIOZ revenue fell 66% year-over-year to $5.6M, pressured by generic competition and inventory destocking; $7M in orders slipped into Q3.
-
Cash Burn Accelerates
Cash, equivalents, and marketable securities dropped to $170.0M from $263.8M at year-end 2025; operating cash outflow was $81.3M in the first half.
-
New Tariff Risk Emerges
A 100% tariff on patented pharmaceutical imports takes effect September 29, 2026, threatening margins and supply chains for Vanda's products.
Analysis · VNDA · Life Sciences
Vanda's second-quarter loss more than doubled year-over-year to $62.5 million, fueled by a 66% collapse in HETLIOZ sales alongside sharply higher R&D and commercial spending. Cash and securities tumbled by $94 million over six months to $170 million, intensifying concerns about the company's runway. To offset the HETLIOZ decline, management is counting on new launches—BYSANTI in the second half of 2026 and a potential Quimilza approval in December—but execution risk remains elevated. Adding a fresh threat to margins and supply chains, a 100% tariff on patented drug imports takes effect September 29.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNDA was trading at $4.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $306.1M. The 52-week trading range was $4.14 to $9.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.